Tejas Savant
Stock Analyst at Morgan Stanley
(3.19)
# 1,128
Out of 5,130 analysts
250
Total ratings
48.23%
Success rate
1.08%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $42.04 | +14.18% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $618.86 | +8.26% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $66.27 | +28.26% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $21.06 | +13.96% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $8.10 | +35.80% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $234.31 | +13.10% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $242.41 | +9.32% | 12 | Dec 2, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $85 → $110 | $100.10 | +9.89% | 3 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $20.46 | -2.25% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $74.87 | +1.51% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $15.78 | +1.43% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $141.07 | -25.57% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $12.41 | -3.30% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $13.16 | -39.21% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $5.45 | +28.44% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $10.55 | -33.65% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.93 | +27.23% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $6.58 | +219.15% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.94 | +3.09% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $9.24 | +332.90% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.06 | +191.26% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $5.29 | +89.04% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.13 | -12.14% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.95 | +412.82% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $110.17 | -33.74% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $220.91 | +13.17% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $5.46 | +1,731.50% | 5 | May 12, 2022 |
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $42.04
Upside: +14.18%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $618.86
Upside: +8.26%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $66.27
Upside: +28.26%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $21.06
Upside: +13.96%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $8.10
Upside: +35.80%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $234.31
Upside: +13.10%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $242.41
Upside: +9.32%
GRAIL
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $85 → $110
Current: $100.10
Upside: +9.89%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $20.46
Upside: -2.25%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $74.87
Upside: +1.51%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $15.78
Upside: +1.43%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $141.07
Upside: -25.57%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $12.41
Upside: -3.30%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $13.16
Upside: -39.21%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $5.45
Upside: +28.44%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $10.55
Upside: -33.65%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.93
Upside: +27.23%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $6.58
Upside: +219.15%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.94
Upside: +3.09%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $9.24
Upside: +332.90%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.06
Upside: +191.26%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $5.29
Upside: +89.04%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.13
Upside: -12.14%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.95
Upside: +412.82%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $110.17
Upside: -33.74%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $220.91
Upside: +13.17%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $5.46
Upside: +1,731.50%